

ASX ANNOUNCEMENT

MARKET RELEASE

12 November 2024

Successful A\$5 million placement

Highlights

- Binding commitments received for A\$5 million under a placement to sophisticated or professional investors (Placement) at A\$0.42 per share (Placement Price).
- Placement strongly supported with demand in excess of the funds sought.
- Placement introduces Healthliant Ventures (the venture arm of US hospital system Tanner Health) and a number of highly credentialed institutional and high net worth investors to the register.
- Placement proceeds will be allocated toward product development, clinical, research and development, regulatory work, IT infrastructure and security, and working capital in advance of the anticipated FDA clearance of the Company's patented Salix® Coronary Anatomy product.

Artrya Limited (ASX:AYA), ('Artrya' or the 'Company'), is pleased to announce it has received binding commitments for a A\$5 million placement at A\$0.42 per share.

The Placement supports the ongoing commercialisation of the Company's patented AI platform that detects key coronary artery disease imaging markers. Placement proceeds will be applied to product development, clinical, research and development, regulatory work, IT infrastructure and security, and working capital.

Petra Capital acted as sole lead manager and sole bookrunner to the Placement.

Artrya CEO Mathew Regan said:

"We are delighted with the support for the Placement and welcome a number of new highly credentialed investors to the register, alongside Healthliant Ventures, the venture arm of US hospital system Tanner Health. On behalf of the Board of Directors I would also like to thank our existing shareholders for their ongoing support."

At this pivotal moment for the Company, the Placement supports and accelerates our ongoing initiatives as we await regulatory clearance from the US Food and Drug Administration (FDA) for the Salix® Coronary Anatomy product.

Placement Details

The A\$5 million placement has been completed at a Placement Price of A\$0.42 per share representing a 16.0% discount to the last closing price and a 17.9% discount to the 5-day volume weighted average trading price as of 7 November 2024.

Total Placement shares of 11,904,762 will be issued under the Company's remaining placement capacity (4,029,363 under ASX Listing Rule 7.1 and 7,875,399 under ASX Listing Rule 7.1A). In addition, the Company will issue under ASX Listing Rule 7.1. 1,190,476 new options to Petra Capital with an exercise price of A\$0.63 and expiry of 2 years from issue.

The Placement is expected to settle on 18 November 2024 with allotment on or around 19 November 2024.

This announcement was approved by the Board.

For further information please contact:

Investor Enquiries:

Danny Younis

[+61 420 293 042](tel:+61420293042)

danny.younis@automicgroup.com.au

Media Relations:

Tristan Everett

+61 403 789 096

tristan.everett@automicgroup.com.au

About Artrya

Based in Perth, Australia, Artrya was founded in 2018 with operations starting in early 2019. The Company was listed on the Australian Securities Exchange (ASX: AYA) in 2021.

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of at-risk patients. The company has developed deep-learning algorithms pending regulatory submission for clearance and approval in the US that will serve to predict and prevent acute coronary events.

For more information, see www.artrya.com

For personal use only

Artrya Limited
ACN 624 005 741
1257 Hay Street West Perth WA 6005
PO Box 567 West Perth WA 6872
www.artrya.com
T: +61 8 6478 7816